ADM, a global leader in innovative solutions from nature, announced that Fibersol^®, a premier line of soluble prebiotic fibers, has received approval from the Therapeutic Goods Administration (TGA), part of the Australian Department of Health, for use as an active ingredient in biologicals, listed medicines, and prescription medicines. The approval expands Fibersol^®’s role beyond conventional food and beverage applications into dietary supplements and other regulated health product categories.

“Securing TGA approval for Fibersol^® marks a significant development for ADM,” said Helen Hu, president of health & wellness APAC at ADM. “It allows our customers to highlight Fibersol^®’s clinically supported health benefits on packaging, providing clear value in a category where consumer trust is essential. In today’s dynamic health and wellness market, regulatory approvals are more than a requirement; they are a mark of credibility. With this approval, ADM continues to deliver science-backed solutions that give brands a competitive edge and consumers greater confidence in their choices.”

Backed by more than 100 scientific publications, Fibersol^® has been extensively researched, demonstrating its potential across a wide range of health indications. Clinically documented results show that Fibersol^®:

• Promotes the growth of beneficial gut bacteria^1,2
• Supports a healthy gut microbiota and overall digestive health^1,2
• Nourishes intestinal flora and maintains a balanced intestinal environment²
• May delay hunger and support normal production of GLP-1 and peptide yy³
• Consumption of Fibersol-2^™ is associated with a reduction in the uptake of sugars from dietary carbohydrates and in the absorption of dietary triglycerides^4,5

In addition to its clinically supported benefits, Fibersol^® is well-tolerated and versatile⁶, with stability observed under heat, acid, shear, and freeze/thaw conditions. Its neutral taste profile makes it easy to incorporate across foods, beverages, and dietary supplements, enabling brands to deliver enjoyable, gut- friendly products without compromising on taste or texture.

The prebiotics market in Australia is projected to grow at a CAGR of 17.6 % between 2024 and 2030⁷, driven by rising consumer focus on digestive health. Nearly 40 % of Australian consumers have taken steps to improve their digestive health in the past year, of which more than one-third (39 %) are choosing supplements and vitamins to support this goal⁸, highlighting a shift toward targeted, science-backed solutions.

This growing interest in digestive health aligns with the expanding role of prebiotic fibers in supplements and functional products. ADM’s latest approval adds to its portfolio of TGA-recognised ingredients, following DE111^™ in 2024, and underscores Fibersol^®’s strong clinical foundation.

¹Fahey, GC. J. Nutr., 130, 1267-1273
²Burns A. (2018). Nutrition Research, 60, 33-42
³Ye, Z. (2015). Nutritional Research, 35, 393-400
⁴Yuasa, M. et al. (2004). Jpn Innov Food Ingred Res, 7:83-93
⁵Tanaka, T. et al. (2011), Jpn Pharmocol Ther., 339: 813-821 Randomized double-blind crossover study (73 subjects) on carbonated beverage with 5g resistant maltodextrin taken with high fat meal (42 g fat) showed significantly lower postprandial serum triglycerides compared to placebo
⁶Kishimoto, Y., et al. (2013) J. Nutr. Sci. Vitaminol (Tokyo) 59(4):352-7
⁷Grand View Research, Australia Prebiotics Market Size & Outlook, 2023-2030
⁸ADM Outside Voice Lifestyle Survey 2025

Symrise sets out to make a strong impact at Vitafoods Europe 2025 in Barcelona from May 20–22. At booth 4D55, visitors can explore cutting-edge health solutions sourced from nature and backed by science. A major highlight includes the upcoming completion of the Probi acquisition and its ongoing integration into Symrise.

Symrise will unveil three human health solutions at the trade show. These products address key areas, including joint health & mobility, urinary health, and healthy aging. Also, the upcoming completion of the Probi acquisition will form a special highlight.

Launch of human health solutions to address industry challenges and consumer wishes

Chondractiv^™ Move: The 4-in-1 mobility solution supports an active lifestyle, featuring type II collagen peptides, chondroitin sulfate, hyaluronic acid, and rosehip polyphenols. Chondractiv^™ Move is suitable for food supplements, functional foods, and beverages, targeting 35+consumers who look for solutions to support their joints and maintain their mobility.

Cranpure^™ M: A women health solution to support urinary health at a daily dose of 300mg. Gently processed from the high-PAC Mullica Queen^® variety, this cranberry powder contains high levels of proanthocyanidins (PACs) and offers a high in vitro anti-adhesion efficacy at a competitive price.

Acerowell^™: The solution can contribute to healthy aging by supporting metabolic health and skin anti-aging from within. Acerowell^™ is a unique acerola product with complete polyphenol characterization and standardization. This allows consumers to harness the full benefits of acerola’s vitamin C and polyphenols.

In addition, six forward-thinking product concepts will showcase how Symrise combines health actives with great taste. “We have designed our concepts to help meet evolving consumer demands in trending formats like soft chews or shots. By leveraging proprietary tools like Symvision^™ AI, Symrise can decode emerging flavor, taste, and claim trends with precision. In addition, the ConceptScan^™ platform can validate these concepts directly with consumers — ensuring they deliver both health benefits and a great sensory experience” says Clémence Boutin, Application Manager Health EMEA, Symrise Food & Beverage.

Probi strengthens Symrise’s health portfolio with clinically proven biotic solutions

The upcoming integration of Probi, a leading provider of biotic solutions, into the Symrise family marks a key milestone in Symrise’s “One Care” journey. Its strong scientific heritage and portfolio of clinically proven biotic solutions promote health and well-being. With that, it perfectly complements and strengthens the Symrise offer. At Vitafoods, Probi will introduce two powerful biotic solutions:

Mental Health by Probi^®: Featuring L. plantarum HEAL9 (HEAL9^®). Four clinical trials and over 30 publications have explored the HEAL9 strain’s impact on the gut-brain axis, showing significant improvements in cognition, mood, sleep, and stress, contributing to overall mental wellness.

Metabolic Health by Probi^®: A major European launch, combining the strength of L. plantarum 299V (LP299V^®) and L. paracasei 8700:2^™. A total of nine clinical trials demonstrate the efficacy of these strains, showing their potential to support metabolic health, reduce risk markers of metabolic syndrome and supporting cardiovascular health.